P46 Effect of extra-fine triple therapy (BDP/FF/GB) pressurized metered-dose inhaler (pMDI) on patient reported outcomes in East Asian patients with COPD: TRIVERSYTI study interim analysis results

Introduction and ObjectivesThe COPD Assessment Test (CAT) and Saint George Respiratory Questionnaire (SGRQ) are reliable instruments for monitoring health status changes in clinical trials. We present here the interim analysis results of the TRIVERSYTI study on these secondary patient-reported outcome measures in East Asian patients with COPD.MethodsTRIVERSYTI is an ongoing phase III multi-centre (China, South Korea and Taiwan), randomized, parallel group trial comparing a 24-week treatment with (BDP/FF/GB) 100/6/12.5 µg pMDI, 2 puffs bid to BUD/FF 160/4.5 µg DPI (Turbuhaler®, AstraZeneca) 2 inhalations bid, in adults with COPD, post-bronchodilator FEV1